ERBB2 and breast cancer: Consistent with previous study [8], our present study also showed that pCR rates vary according to ER/PR status, with the highest rates observed in ER-PR-HER2-positive breast cancer patients and the lowest in the ER + PR + HER2-positive breast cancer patients.